Cargando…
Clinical development of the GnRH agonist leuprolide acetate depot
Leuprolide acetate is the first GnRH agonist that entered clinical development after the discovery of the native GnRH. Several long-acting depot formulations of leuprolide acetate (ranging from 1-month to 6-month intramuscular injections) have been successively developed for various suppressive trea...
Autor principal: | Chwalisz, Kristof |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10201295/ https://www.ncbi.nlm.nih.gov/pubmed/37223757 http://dx.doi.org/10.1016/j.xfre.2022.11.011 |
Ejemplares similares
-
GnRH agonists in the treatment of symptomatic endometriosis: a review
por: Surrey, Eric S.
Publicado: (2022) -
Effect of Leuprolide Acetate, a GnRH Agonist, on Neuroinflammation and Anxiety-Like Behavior after Mild Hypoxic-Ischemic Encephalopathy in Rat Model
por: Pedroza-García, Karina Alejandra, et al.
Publicado: (2023) -
Leuprolide Acetate 1-Month Depot for Central Precocious Puberty: Hormonal Suppression and Recovery
por: Neely, E. Kirk, et al.
Publicado: (2010) -
Comparison of GnRH Agonist, GnRH Antagonist, and GnRH Antagonist Mild Protocol of Controlled Ovarian Hyperstimulation in Good Prognosis Patients
por: Stimpfel, Martin, et al.
Publicado: (2015) -
GnRH agonist versus GnRH antagonist in assisted reproduction cycles: oocyte morphology
por: Cota, Ana Marcia M, et al.
Publicado: (2012)